465 related articles for article (PubMed ID: 20172036)
21. Inhibition of the HERG channel by droperidol depends on channel gating and involves the S6 residue F656.
Luo T; Luo A; Liu M; Liu X
Anesth Analg; 2008 Apr; 106(4):1161-70, table of contents. PubMed ID: 18349188
[TBL] [Abstract][Full Text] [Related]
22. Strategies to reduce HERG K+ channel blockade. Exploring heteroaromaticity and rigidity in novel pyridine analogues of dofetilide.
Carvalho JF; Louvel J; Doornbos ML; Klaasse E; Yu Z; Brussee J; IJzerman AP
J Med Chem; 2013 Apr; 56(7):2828-40. PubMed ID: 23473309
[TBL] [Abstract][Full Text] [Related]
23. Block of HERG-carried K+ currents by the new repolarization delaying agent H 345/52.
Amos GJ; Jacobson I; Duker G; Carlsson L
J Cardiovasc Electrophysiol; 2003 Jun; 14(6):651-8. PubMed ID: 12875428
[TBL] [Abstract][Full Text] [Related]
24. Automated electrophysiology in the preclinical evaluation of drugs for potential QT prolongation.
Guo L; Guthrie H
J Pharmacol Toxicol Methods; 2005; 52(1):123-35. PubMed ID: 15936217
[TBL] [Abstract][Full Text] [Related]
25. The human ether-a'-go-go related gene (hERG) K+ channel blockade by the investigative selective-serotonin reuptake inhibitor CONA-437: limited dependence on S6 aromatic residues.
Alexandrou AJ; Milnes JT; Sun SZ; Fermini B; Kim SC; Jenkinson S; Leishman DJ; Witchel HJ; Hancox JC; Leaney JL
J Physiol Pharmacol; 2014 Aug; 65(4):511-23. PubMed ID: 25179083
[TBL] [Abstract][Full Text] [Related]
26. Development of recombinant cell line co-expressing mutated Nav1.5, Kir2.1, and hERG for the safety assay of drug candidates.
Fujii M; Ohya S; Yamamura H; Imaizumi Y
J Biomol Screen; 2012 Jul; 17(6):773-84. PubMed ID: 22498908
[TBL] [Abstract][Full Text] [Related]
27. Molecular interaction of droperidol with human ether-a-go-go-related gene channels: prolongation of action potential duration without inducing early afterdepolarization.
Schwoerer AP; Blütner C; Brandt S; Binder S; Siebrands CC; Ehmke H; Friederich P
Anesthesiology; 2007 May; 106(5):967-76. PubMed ID: 17457128
[TBL] [Abstract][Full Text] [Related]
28. Blockade of the human ether-a-go-go-related gene potassium channel by ketanserin.
Tu DN; Zou AR; Liao YH; Du YM; Wang XP; Li L
Sheng Li Xue Bao; 2008 Aug; 60(4):525-34. PubMed ID: 18690396
[TBL] [Abstract][Full Text] [Related]
29. Variability in the measurement of hERG potassium channel inhibition: effects of temperature and stimulus pattern.
Kirsch GE; Trepakova ES; Brimecombe JC; Sidach SS; Erickson HD; Kochan MC; Shyjka LM; Lacerda AE; Brown AM
J Pharmacol Toxicol Methods; 2004; 50(2):93-101. PubMed ID: 15385083
[TBL] [Abstract][Full Text] [Related]
30. Inactivation gating determines drug potency: a common mechanism for drug blockade of HERG channels.
Yang BF; Xu DH; Xu CQ; Li Z; Du ZM; Wang HZ; Dong DL
Acta Pharmacol Sin; 2004 May; 25(5):554-60. PubMed ID: 15132818
[TBL] [Abstract][Full Text] [Related]
31. Inhibition of cardiac HERG currents by the DNA topoisomerase II inhibitor amsacrine: mode of action.
Thomas D; Hammerling BC; Wu K; Wimmer AB; Ficker EK; Kirsch GE; Kochan MC; Wible BA; Scholz EP; Zitron E; Kathöfer S; Kreye VA; Katus HA; Schoels W; Karle CA; Kiehn J
Br J Pharmacol; 2004 Jun; 142(3):485-94. PubMed ID: 15148258
[TBL] [Abstract][Full Text] [Related]
32. Effect of compound plate composition on measurement of hERG current IC(50) using PatchXpress.
Mo ZL; Faxel T; Yang YS; Gallavan R; Messing D; Bahinski A
J Pharmacol Toxicol Methods; 2009; 60(1):39-44. PubMed ID: 19442753
[TBL] [Abstract][Full Text] [Related]
33. State dependent dissociation of HERG channel inhibitors.
Stork D; Timin EN; Berjukow S; Huber C; Hohaus A; Auer M; Hering S
Br J Pharmacol; 2007 Aug; 151(8):1368-76. PubMed ID: 17592502
[TBL] [Abstract][Full Text] [Related]
34. Molecular determinants of cocaine block of human ether-á-go-go-related gene potassium channels.
Guo J; Gang H; Zhang S
J Pharmacol Exp Ther; 2006 May; 317(2):865-74. PubMed ID: 16397089
[TBL] [Abstract][Full Text] [Related]
35. H(1) antihistamine drug promethazine directly blocks hERG K(+) channel.
Jo SH; Hong HK; Chong SH; Lee HS; Choe H
Pharmacol Res; 2009 Nov; 60(5):429-37. PubMed ID: 19497368
[TBL] [Abstract][Full Text] [Related]
36. Extracellular potassium dependency of block of HERG by quinidine and cisapride is primarily determined by the permeant ion and not by inactivation.
Barrows B; Cheung K; Bialobrzeski T; Foster J; Schulze J; Miller A
Channels (Austin); 2009; 3(4):239-48. PubMed ID: 19617705
[TBL] [Abstract][Full Text] [Related]
37. Discovery of a small molecule activator of the human ether-a-go-go-related gene (HERG) cardiac K+ channel.
Kang J; Chen XL; Wang H; Ji J; Cheng H; Incardona J; Reynolds W; Viviani F; Tabart M; Rampe D
Mol Pharmacol; 2005 Mar; 67(3):827-36. PubMed ID: 15548764
[TBL] [Abstract][Full Text] [Related]
38. Comparative effects of the short QT N588K mutation at 37 degrees C on hERG K+ channel current during ventricular, Purkinje fibre and atrial action potentials: an action potential clamp study.
McPate MJ; Zhang H; Adeniran I; Cordeiro JM; Witchel HJ; Hancox JC
J Physiol Pharmacol; 2009 Mar; 60(1):23-41. PubMed ID: 19439805
[TBL] [Abstract][Full Text] [Related]
39. Characterization of loperamide-mediated block of hERG channels at physiological temperature and its proarrhythmia propensity.
Sheng J; Tran PN; Li Z; Dutta S; Chang K; Colatsky T; Wu WW
J Pharmacol Toxicol Methods; 2017; 88(Pt 2):109-122. PubMed ID: 28830713
[TBL] [Abstract][Full Text] [Related]
40. Intracellular K+ is required for the inactivation-induced high-affinity binding of cisapride to HERG channels.
Lin J; Guo J; Gang H; Wojciechowski P; Wigle JT; Zhang S
Mol Pharmacol; 2005 Sep; 68(3):855-65. PubMed ID: 15967876
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
